ClinicalTrials.gg
CompletedNCT03698513Updated Sep 29, 2021

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

A Phase 1 interventional study of BMS-986177 and Placebo (for BMS-986177) in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will investigate the safety and interaction of BMS-986177 in healthy volunteers, when administered with Aspirin and/or Clopidogrel

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Must have a (BMI) of 18.0 to 32.0 kg/m2, inclusive.
  • Must have a normal renal function at screening as evidenced by an estimated (GFR) of > 80 mL/min/1.73 m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula and the absence of protein in the urine

For Parts 1 and 2:

  • Must be a clopidogrel responder (eg, a decrease in aggregation of at least 30% after a single 600-mg dose of clopidogrel compared with baseline).

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness, including tinnitus or any other condition listed as a in the aspirin package insert.
  • History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for 1 week's duration in the last month prior to study treatment administration).
  • History of head injury in the last 2 years, including participants with base skull fractures, intracranial tumor, or aneurysm.
  • History of gastroesophageal reflux disease, dyspepsia (indigestion), protracted nausea, or chronic diarrhea (defined as 3 or 4 loose stools per day that last for ≥ 4 weeks) within the past 6 months.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    BMS-986177 + Aspirin + Clopidogrel (Part 1)

    BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    BMS-986177 (Part 1)

    BMS-986177 200 mg capsule twice daily (days 1-5)

    Drug: BMS-986177

  • Placebo comparator
    BMS-986177 placebo + Aspirin + Clopidogrel (Part 1)

    BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)

    Other: Placebo (for BMS-986177) · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    BMS-986177 (Part 2)

    BMS-986177 200 mg capsule twice daily (days 1-5)

    Drug: BMS-986177

  • Placebo comparator
    BMS-986177 placebo + Clopidogrel (Part 2)

    BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)

    Other: Placebo (for BMS-986177) · Drug: Clopidogrel

  • Experimental
    BMS-986177 + Clopidogrel (Part 2)

    BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)

    Drug: BMS-986177 · Drug: Clopidogrel

  • Experimental
    BMS-986177 (Part 3)

    BMS-986177 200 mg capsule twice daily (days 1-5)

    Drug: BMS-986177

  • Placebo comparator
    BMS-986177 placebo + Aspirin (Part 3)

    BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)

    Other: Placebo (for BMS-986177) · Drug: Aspirin

  • Experimental
    BMS-986177 + Aspirin (Part 3)

    BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)

    Drug: BMS-986177 · Drug: Aspirin

Interventions

  • BMS-986177 capsule

  • OtherPlacebo (for BMS-986177)

    BMS-986177 placebo match capsule

  • Clopidogrel tablet

  • Aspirin tablet

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to Day 33

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to Day 95

  3. Incidence of Adverse Events (AEs) leading to discontinuation

    Time frame: Up to Day 33

  4. Number of participants with vital sign abnormalities

    Time frame: Up to Day 33

  5. Number of participants with 12-lead electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 33

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 33

  7. Number of participants with physical examination abnormalities

    Time frame: Up to Day 33

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Cmax of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite

    Time frame: Up to Day 33

  2. Area under the plasma concentration time curve in one dosing interval [AUC(TAU)]

    AUC(TAU) of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite

    Time frame: Up to Day 33

  3. Time of maximum observed concentration (Tmax)

    Tmax of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite

    Time frame: Up to Day 33

  4. Terminal plasma half-life (T-HALF)

    T-Half of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite

    Time frame: Up to Day 33

  5. Trough observed plasma concentration (Ctrough)

    Ctrough of BMS-986177, acetylsalicylic acid, salicylic acid, clopidogrel and clopidogrel metabolite

    Time frame: Up to Day 26

  6. Apparent total body clearance (CLT/F)

    CLT/F of BMS-986177, aspirin, clopidogrel

    Time frame: Up to Day 33

  7. Volume of distribution (Vz/F)

    Vz/F of BMS-986177, aspirin, clopidogrel

    Time frame: Up to Day 33

07

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2018
First posted
Oct 9, 2018
StartActual
Oct 4, 2018
Primary completionActual
Feb 19, 2019
CompletionActual
Feb 19, 2019
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03698513
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Oct 4, 2018
Primary completion
Feb 19, 2019
Completion
Feb 19, 2019
Last update
Sep 29, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Milvexian · Clopidogrel · Aspirin

Start the discussion